1990 Volume 38 Issue Supplement1 Pages 322-330
From our laboratory and clinical studies on cefetamet pivoxil (CEMT-PI) the following results were obtained.
1) Antibacterial activity: the MIC level was greater than 12.5, ugiml against 14 strains of Staphylococcus aureus. The peak MIC were at 0.1μg/ml against 13 strains of Proteus mirabilis and greater than 100 geml against 16 strains of Pseudomonas aeruginosa.
2) Tissue concentration: palatine tonsil and serum levels were 1.09-2.76 μg/g, 5.09-6.25μg/ml at 3°16'-4°00' after 500mg p.o. fasting. The rate of tissue/serum was 19.9-45.5%. The mucosal levels of maxillary sinus and serum levels were 1.13-2.76 μg and 1.46-4.69μg/ml at 2°46'-4°38' after 500mg p.o. fasting. The rate of tissue/serum was 48.1-106.9%. Otorrhea and serum levels were <0.2-1.46μg/ml and 1.96-7.82μg/ml at 1°15'-4°00' after 500mg p.o. non-fasting. The rate of otorrhea/serum was 10.0-37.5%. Palatine tonsil and serum levels were 0.75μg/g and 1.96 μg/ml at 2°43' after 250mg p.o. fasting. The rate of tissue/serum was 38.3%.
3) Clinical results: CEMT-PI was used clinically in 56 cases of various infections in otorhinolaryngological infection. The clinical result was excellent in 20, good in 24, fair in 6, poor in 4 cases and unknown in 2 cases. The efficacy rate was 81.5%.
4) Adverse reaction: no adverse reactions were observed.
